We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Bio-Techne

Bio-Techne Corporation is a developer and manufacturer of high-quality purified proteins and reagent solutions - nota... read more Featured Products: More products

Download Mobile App




Bio-Techne and ALZpath Partner to Advance Neurodegenerative Disease Research and Treatment

By LabMedica International staff writers
Posted on 19 Nov 2024
Print article
Image: The Simple Plex Human Phospho Tau 217 ALZpath assay runs on the Ella automated immunoassay platform (Photo courtesy of Bio-Techne)
Image: The Simple Plex Human Phospho Tau 217 ALZpath assay runs on the Ella automated immunoassay platform (Photo courtesy of Bio-Techne)

Bio-Techne Corporation (Minneapolis, MN, USA) and ALZpath, Inc. (Carlsbad, CA, USA) have entered into a strategic partnership to accelerate breakthroughs in neurodegenerative disease research and treatment, including Alzheimer's disease. The collaboration leverages Bio-Techne's Ella fully automated, multiplexing immunoassay platform and ALZpath's proprietary pTau217 antibody to provide the Simple Plex Human Phospho-Tau (T217) ALZpath Assay.

The ALZpath pTau217 (phosphorylated Tau217) antibody is the leading antibody used to detect the pTau217 biomarker. Increased levels of pTau217 are associated with amyloid plaques and tau tangles, the hallmark features of Alzheimer's disease. By running the Simple Plex Human Phospho Tau 217 ALZpath Assay on the Ella system, researchers will be able to detect the pTau217 signal in less invasive sample collection types, such as plasma samples, in just 90 minutes without any manual intervention, improving efficiency, scalability, and precision while providing the required information to help accelerate clinical decisions.

"Our partnership with ALZpath represents a major step forward in our commitment to advancing neurodegenerative disease research," said Will Geist, President of Bio-Techne's Protein Sciences Segment. "We're excited to see the impact that this easy-to-use, hands-free platform will have on advancing research in this critical field."

"As cases of Alzheimer's disease continue to rise around the world, this collaboration provides an opportunity to leverage our proprietary pTau217 antibody to advance promising research and development of new treatments," said Chad Holland, CEO at ALZpath. "The integration of our pTau217 antibody into Bio-Techne's advanced immunoassay technology creates a unique toolset that will empower researchers around the world to explore new methods of treatment and validate benefits that may result from those interventions, pushing the industry forward."

Related Links:
Bio-Techne Corporation

ALZpath, Inc.

Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
New
Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
Silver Member
L-Homocysteine Assay
Homocysteine (HCY) 2 Reagent Enzymatic Assay
New
Human Thyroglobulin Assay
Human Thyroglobulin CLIA Kit

Print article

Channels

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Pathology

view channel
Image: The skin-based test can detect signature features of progressive supranuclear palsy (Photo courtesy of 123RF)

Skin-Based Test to Improve Diagnosis of Rare, Debilitating Neurodegenerative Disease

In neurodegenerative diseases, misfolded proteins, such as alpha synuclein or tau, accumulate in brain and nervous system cells, leading to cell damage and neurodegeneration. While researchers have successfully... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.